Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
Patients Can Help Move the Needle Forward in Bladder Cancer Clinical Trials With Participation
September 29th 2022As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how patients can find clinical trials they may be eligible for.
Combining Old and New Therapies in Advanced Bladder Cancer Shows Promise for the Future
September 29th 2022As part of its “Speaking Out” video series, CURE spoke with Dr. Tracy L. Rose, on behalf of the Bladder Cancer Advocacy Network, about how currently available agents are being investigated in combination with one another.
Longer Hormone Therapy After Main Treatments Delays Prostate Cancer Metastasis
September 13th 2022Two years of the hormone treatment androgen-deprivation therapy (ADT) after radiotherapy and radical prostatectomy tended to improve metastasis-free survival for patients with prostate cancer, study results showed.